M&A Deal Summary

Ironwood Pharmaceuticals Acquires VectivBio

On May 22, 2023, Ironwood Pharmaceuticals acquired life science company VectivBio for 1.0B USD

Acquisition Highlights
  • This is Ironwood Pharmaceuticals’ 1st transaction in the Life Science sector.
  • This is Ironwood Pharmaceuticals’ largest (disclosed) transaction.
  • This is Ironwood Pharmaceuticals’ 1st transaction in Switzerland.

M&A Deal Summary
Date 2023-05-22
Target VectivBio
Sector Life Science
Buyer(s) Ironwood Pharmaceuticals
Deal Type Add-on Acquisition
Deal Value 1.0B USD
Advisor(s) Centerview Partners
BofA Securities (Financial)
Cooley LLP
Homburger (Legal)

Target

VectivBio

Basel, Switzerland
website
VectivBio is a clinical-stage biotechnology company focused on rare diseases with well-defined biology that can be targeted with transformational therapeutics. VectivBio was formed in 2019 as a spinout from Therachon, a biotechnology company acquired by Pfizer, Inc., for its program in achondroplasia, with the ambition to continue to have an impact on people’s lives by bringing transformational medicines to patients with serious rare conditions. VectivBio is based in Basel, Switzerland.

Search 192,349 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Ironwood Pharmaceuticals

Boston, Massachusetts, United States

website

Category Company
Founded 1998
Sector Life Science
Employees219
Revenue 414M USD (2021)
DESCRIPTION

Ironwood Pharmaceuticals is a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Mexico, as well as under the CONSTELLA name in the Canada and European Union. Ironwood Pharmaceuticals was founded in 1998 and is based in Boston, Massachusetts.

DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Add-on Acquisition) 1 of 1
Country (Switzerland) 1 of 1
Year (2023) 1 of 1
Size (of disclosed) 1 of 1
Mergr

Product

Company

Legal